Dr. Gillis is Managing Director at ARCH Venture Partners. He is focused on the evaluation of new life science technologies and on the development and growth of ARCH’s biotechnology portfolio companies.
He is a director of 48 Bio, Pheast Therapeutics, beBio, SonoThera, Dispatch Bio, and Carrick Therapeutics. He serves as Chairman and director of Faraday Pharmaceuticals, eGenesis, HiberCell, hC Bioscience, Skylark Bio, Walden Biosciences, OncoResponse, Mozart Therapeutics, Bitterroot Bio, Vilya, Lifordi Immunotherapeutics, Basking Bio, TFC Therapeutics, Proniras, and VBI Vaccines (VBIV). Dr. Gillis also serves as a director of Takeda Pharmaceuticals (TAK).
Dr. Gillis was a founder and director of Corixa Corp., serving as CEO from its inception and as Chairman from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corp., the most successful venture-funded biotech company in the state of Washington. From 1981 until his departure in 1994, he served as Immunex’s Director of Research and Development, Chief Scientific Officer, and as CEO of Immunex’s R&D subsidiary. Dr. Gillis was interim CEO of Immunex following its majority purchase by American Cyanamid Co. and remained a member of the board until 1997. Amgen, Inc. acquired Immunex in 2002.
Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20).
Dr. Gillis received a B.A. from Williams College and a Ph.D. from Dartmouth College.
Dr. Booth is currently chairman of Arkuda Therapeutics, Hotspot Therapeutics, Kymera Therapeutics (NASDAQ:KYMR), Matchpoint Therapeutics, Nimbus Therapeutics, and Vigil Neuroscience (NASDAQ: VIGL). He also serves on the boards of Lifordi and Sionna Therapeutics, and several seed stage companies. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics (acquired by Bial), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), and a number of other ventures.
He serves or has served as an advisor in various capacities to Takeda, UCB, the Gates Foundation, Dana Farber’s Binney Street Capital, and the Penn State Research Foundation. He also serves on the board of New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com.
Prior to joining Atlas in 2005, he was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.
Dr. Booth enjoys running, skiing, hiking, and fishing, and has three wonderful kids.
Mr. DeLucia has over 35 years of experience in the biopharmaceutical industry including early-stage drug development, business development and management of strategic partnerships.
Mr. DeLucia is Co-Founder of Cascador, a program for mid-stage entrepreneurs in Africa who are scaling mission-driven companies. Mr. DeLucia also co-founded and was CEO of ImmuNext, an immunotherapy-based company, and CEO of MIST Inc., a breast cancer imaging company. Prior to MIST, he led the development of a drug development technology platform at Millennium Pharmaceuticals which was spun out as part of a separate company in 2003.
He has an M.S. from MIT and a B.A. from Dartmouth College.
Dr. Smith is a distinguished leader in biopharmaceutical development with over two decades of experience driving innovation in oncology, gene therapy, and immunotherapy. Currently, she serves as the President of Triangle Therapeutics Consulting, LLC and holds a position on the Board of Directors at Lifordi Immunotherapeutics. Dr. Smith has held key leadership roles at SpringWorks Therapeutics, where she led the development and FDA approval of Ogsiveo®, the first GSI approved for desmoid tumors, and led the development of mirdametinib for neurofibromatosis.
Her career includes pivotal contributions at United Therapeutics Corporation, where she was instrumental in the approval of Unituxin®, the first immunotherapy for high-risk neuroblastoma in both the U.S. and Europe. Dr. Smith’s work has consistently focused on advancing treatments for rare and complex diseases, demonstrating her commitment to improving patient outcomes through innovative medical solutions.
She earned her PhD in Microbiology from the University of New Hampshire and has published extensively in leading medical journals.
Katie Spielberg, Ph.D. is a Principal on the Investment Team at 5AM Ventures, based in the Boston, MA office. Dr. Spielberg is currently a Board Member or Observer for Lifordi Immunotherapeutics, GlycoEra and a stealth 4:59 newco. She was named the New England Venture Capital Association’s 2024 Rising Star VC.
Prior to joining 5AM, she completed both a postdoctoral fellowship and a Ph.D. in the Bioengineering department at Stanford University. As a recipient of the Hertz Foundation Fellowship and Stanford Graduate Fellowship, her research focused on how bacterial viruses help the immune system clear bacterial infections. Dr. Spielberg’s work has been published in Cell Systems and Nature Chemical Biology among others. She received her B.S. in Biological Engineering from MIT with Tau Beta Pi honors.
Dr. Spielberg enjoys watching Boston Ballet performances and is the New Member Co-Chair of the Boston Ballet Young Partners Council.
Arthur O. Tzianabos, Ph.D., is President and CEO of Lifordi Immunotherapeutics and a Venture Partner at 5AM Ventures. He has over 30 years of experience in the biotechnology industry and academia leading teams in the discovery, development, clinical translation and commercialization of new treatments for immunology and rare diseases.
Dr. Tzianabos served as President and CEO of Homology Medicines and later became Chair of the Board prior to its merger with Q32 Bio. Dr. Tzianabos is currently a member of the Board of Directors at Q32 Bio and Chair of the Board of Directors at Stoke Therapeutics. Previously, he was Chair of the Board for Akouos Therapeutics (acquired by Eli Lilly in 2022). He also serves on the Development Board for the University of New Hampshire’s College of Life Sciences and Agriculture. Earlier in his career, Dr. Tzianabos had an active role in the development, approval, and commercial launch of multiple therapies for patients with rare genetic disorders at Shire Pharmaceuticals. He also worked closely with the Business Development and Corporate Venture functions to invest in and acquire new companies and technologies to build Shire’s pipeline.
Dr. Tzianabos is trained as an immunologist and was an Associate Professor of Medicine at Harvard Medical School where he maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. He has published more than 80 scientific papers, reviews, book chapters and patents. Dr. Tzianabos holds a Ph.D. in Microbiology from the University of New Hampshire and a B.S. in Biology from Boston College.